These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27661415)

  • 1. Ivabradine reduced ventricular rate in patients with non-paroxysmal atrial fibrillation.
    Wongcharoen W; Ruttanaphol A; Gunaparn S; Phrommintikul A
    Int J Cardiol; 2016 Dec; 224():252-255. PubMed ID: 27661415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. If inhibition in the atrioventricular node by ivabradine causes rate-dependent slowing of conduction and reduces ventricular rate during atrial fibrillation.
    Verrier RL; Bonatti R; Silva AF; Batatinha JA; Nearing BD; Liu G; Rajamani S; Zeng D; Belardinelli L
    Heart Rhythm; 2014 Dec; 11(12):2288-96. PubMed ID: 25111327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation.
    Verrier RL; Silva AF; Bonatti R; Batatinha JA; Nearing BD; Liu G; Rajamani S; Zeng D; Belardinelli L
    J Cardiovasc Electrophysiol; 2015 Mar; 26(3):329-35. PubMed ID: 25346368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of ivabradine for rate control in atrial fibrillation.
    Turley SL; Francis KE; Lowe DK; Cahoon WD
    Ther Adv Cardiovasc Dis; 2016 Dec; 10(6):348-352. PubMed ID: 27659287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivabradine for rate control in atrial fibrillation.
    Kosiuk J; Oebel S; John S; Hilbert S; Hindricks G; Bollmann A
    Int J Cardiol; 2015 Jan; 179():27-8. PubMed ID: 25464400
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of I(f) in the atrioventricular node as a mechanism for dronedarone's reduction in ventricular rate during atrial fibrillation.
    Verrier RL; Sobrado MF; Pagotto VP; Kanas AF; Machado AD; Varone BB; Sobrado LF; Nearing BD; Zeng D; Belardinelli L
    Heart Rhythm; 2013 Nov; 10(11):1692-7. PubMed ID: 23933296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study.
    Davy JM; Herold M; Hoglund C; Timmermans A; Alings A; Radzik D; Van Kempen L;
    Am Heart J; 2008 Sep; 156(3):527.e1-9. PubMed ID: 18760136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.
    Majewski S; Slomka S; Zielinska-Wyderkiewicz E; Ciebiada M; Gorski P
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):179-88. PubMed ID: 22409211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology.
    Camm AJ; Lau CP
    Drugs R D; 2003; 4(2):83-9. PubMed ID: 12718562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ivabradine for chronic heart rate control in persistent atrial fibrillation. Design of the BRAKE-AF project.
    Fontenla A; López-Gil M; Tamargo-Menéndez J; Matía-Francés R; Salgado-Aranda R; Rey-Blas JR; Miracle-Blanco Á; Mejía-Martínez E; Pastor-Fuentes A; Toquero-Ramos J; Arias MÁ; Montilla I; Gómez de la Cámara A; Arribas F;
    Rev Esp Cardiol (Engl Ed); 2020 May; 73(5):368-375. PubMed ID: 31631048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
    Abdel-Salam Z; Rayan M; Saleh A; Abdel-Barr MG; Hussain M; Nammas W
    Cardiol J; 2015; 22(2):227-32. PubMed ID: 25179314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
    Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K;
    Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ivabradine on cardiac electrophysiology in dogs with age-related atrial fibrillation.
    Li YD; Ji YT; Zhou XH; Jiang T; Hong YF; Li JX; Xing Q; Xiong J; Yusufuaji Y; Tang BP
    Med Sci Monit; 2015 May; 21():1414-20. PubMed ID: 25982136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure.
    Cavusoglu Y; Mert U; Nadir A; Mutlu F; Morrad B; Ulus T
    J Cardiovasc Med (Hagerstown); 2015 Sep; 16(9):603-9. PubMed ID: 24922198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy.
    Böhm M; Borer JS; Camm J; Ford I; Lloyd SM; Komajda M; Tavazzi L; Talajic M; Lainscak M; Reil JC; Ukena C; Swedberg K
    Eur J Heart Fail; 2015 May; 17(5):518-26. PubMed ID: 25801408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
    J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.